Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks

Benzinga · 1d ago

Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy (IgAN) at risk for disease progression was presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2026 and simultaneously published in The New England Journal of Medicine.

ORIGIN 3 met the primary endpoint of statistically significant proteinuria reduction at 36 weeks. In the final efficacy analysis, TRUTAKNA achieved statistical significance in all prespecified endpoints.